학술논문

1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers
Document Type
Abstract
Source
In Annals of Oncology September 2022 33 Supplement 7:S1111-S1111
Subject
Language
ISSN
0923-7534